Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Vinblastine API Manufacturers & Suppliers
4 verified results
All Vinblastine data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 550+
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Vinblastine | CAS No: 865-21-4 | GMP-certified suppliers
A medication that treats various cancers including breast, testicular, lymphomas, and Kaposi’s sarcoma by providing potent antimitotic and antineoplastic effects.
Therapeutic categories
Primary indications
- For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma
Product Snapshot
- Vinblastine is formulated as an injectable small molecule available in solution and lyophilized powder forms for intravenous and parenteral administration
- It is primarily used in oncology for treating various cancers including breast cancer, testicular cancer, lymphomas, neuroblastoma, and Kaposi's sarcoma
- Vinblastine is approved for use in key regulatory markets including the United States and Canada
Clinical Overview
Clinically, vinblastine is indicated for the treatment of several malignancies, including breast cancer, testicular cancer, Hodgkin’s and non-Hodgkin’s lymphomas, neuroblastoma, mycosis fungoides, histiocytosis, and Kaposi’s sarcoma. It is also employed in select cases of lymphomas and other hematologic cancers.
Pharmacodynamically, vinblastine functions as a cell cycle phase-specific agent with immunosuppressive properties. Its antitumor action derives primarily from its ability to inhibit mitosis by binding to tubulin proteins within the mitotic spindle. This interaction prevents microtubule polymerization, leading to mitotic arrest at metaphase and ultimately inducing apoptosis or cell death.
Key pharmacokinetic parameters include metabolism via cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6, with vinblastine acting as a substrate, inhibitor, and inducer within this system. It is a substrate for P-glycoprotein and exhibits a narrow therapeutic index. As a BSEP/ABCB11 substrate and inhibitor, hepatic transport interactions must be considered during therapy.
Safety considerations for vinblastine emphasize its myelosuppressive and cardiotoxic potential, requiring careful monitoring of hematologic parameters and cardiac function. Neurotoxicity, gastrointestinal disturbances, and immunosuppression are noted adverse effects. Because of its narrow therapeutic window and complex drug interaction profile, dose adjustments and therapeutic drug monitoring are important in clinical practice.
Vinblastine is incorporated in various established oncology treatment regimens worldwide. It is available as a chemically defined API with CAS number 865-21-4. For API procurement, sourcing from manufacturers compliant with Good Manufacturing Practice (GMP) standards and adherence to pharmacopeial quality specifications are critical to ensure consistent purity, potency, and safety in formulation processes. Analytical characterization should confirm identity, residual solvents, and impurity profiles consistent with regulatory norms.
Identification & chemistry
| Generic name | Vinblastine |
|---|---|
| Molecule type | Small molecule |
| CAS | 865-21-4 |
| UNII | 5V9KLZ54CY |
| DrugBank ID | DB00570 |
Pharmacology
| Summary | Vinblastine is a vinca alkaloid antineoplastic agent that exerts antitumor effects by binding to tubulin and disrupting microtubule dynamics, leading to mitotic arrest at metaphase and subsequent cell death. It acts as a cell cycle phase-specific inhibitor targeting multiple tubulin isoforms and affecting mitotic spindle formation. Additionally, vinblastine exhibits immunosuppressive properties and is utilized in treating various malignancies including lymphomas and solid tumors. |
|---|---|
| Mechanism of action | The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. |
| Pharmacodynamics | Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (<i>Catharanthus roseus</i>) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects <i>in vitro</i>. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Tubulin alpha-1A chain | Humans | binder |
| Tubulin beta chain | Humans | binder |
| Tubulin delta chain | Humans | binder |
ADME / PK
| Half-life | Triphasic: 35 min, 53 min, and 19 hours |
|---|---|
| Protein binding | 98-99% |
| Metabolism | Hepatic. Metabolism of vinblastine has been shown to be mediated by hepatic cytochrome P450 3A isoenzymes. |
| Route of elimination | The major route of excretion may be through the biliary system. |
Formulation & handling
- Vinblastine is a small molecule vinca alkaloid formulated primarily for intravenous and parenteral administration.
- Low water solubility requires consideration in formulation to ensure appropriate solubilization for injection.
- Avoid co-administration with grapefruit products and St. John's Wort due to significant interaction with CYP3A metabolism affecting drug levels.
Regulatory status
| Lifecycle | The API is approaching patent expiry in the US and Canada, with generic competition expected to increase as patents lapse. Market maturity is advancing, reflecting broader availability and established therapeutic use in these regions. |
|---|
| Markets | Canada, US |
|---|
Supply Chain
| Supply chain summary | Vinblastine is manufactured and packaged by multiple companies, including both originator and generic manufacturers, indicating an established supply chain with several participants. The branded products are primarily present in the US and Canadian markets. Given the presence of various manufacturers and formulations, patent expiry has likely allowed for existing generic competition in these regions. |
|---|
Safety
| Toxicity | Oral, mouse: LD<sub>50</sub> = 423 mg/kg; Oral, rat: LD<sub>50</sub> = 305 mg/kg. |
|---|
- Toxicity oral LD50 in rodents indicates moderate acute toxicity
- Appropriate protective measures are recommended during handling
- Avoid inhalation, ingestion, and skin contact due to potential for systemic toxicity
Vinblastine is a type of Antimicrobial agents
Antimicrobial agents are a vital subcategory within the pharmaceutical industry, specifically developed to combat microbial infections. These agents, also known as antibiotics, play a crucial role in treating various types of bacterial, fungal, viral, and protozoal infections.
Antimicrobial agents act by inhibiting the growth or killing the microorganisms responsible for infections. They target specific cellular components or processes within the microbes, disrupting their vital functions and preventing their proliferation. These agents can be further classified based on their mechanism of action, such as bactericidal (kills bacteria) or bacteriostatic (inhibits bacterial growth).
The development of new antimicrobial agents is a continuous process due to the increasing threat of drug resistance. Pharmaceutical companies invest significant resources in research and development to discover and design novel compounds with improved efficacy and reduced side effects.
Several types of antimicrobial agents are available, including beta-lactams, macrolides, fluoroquinolones, aminoglycosides, and tetracyclines. Each class exhibits a distinct mode of action, making them suitable for treating specific types of infections. Additionally, combination therapies involving multiple antimicrobial agents are often employed to enhance effectiveness and combat resistance.
Antimicrobial agents are utilized not only in human medicine but also in veterinary and agricultural sectors to maintain the health and well-being of animals and plants. Strict regulations and quality control measures are in place to ensure the safety and efficacy of these pharmaceutical APIs.
In conclusion, antimicrobial agents are a crucial subcategory of pharmaceutical APIs that play a pivotal role in fighting microbial infections. Continuous research and development efforts are necessary to combat emerging drug resistance and ensure the availability of effective treatments for various infections.
Vinblastine (Antimicrobial agents), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Vinblastine API manufacturers & distributors
Compare qualified Vinblastine API suppliers worldwide. We currently have 4 companies offering Vinblastine API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Cipla | Producer | India | Unknown | CEP, CoA, USDMF, WC | 164 products |
| Gedeon Richter | Producer | Hungary | Unknown | CEP, CoA, FDA, GMP | 48 products |
| Minakem | Producer | France | Belgium | CEP, CoA, GMP, USDMF | 31 products |
| Zhejiang Hisun Pharma | Producer | China | China | CoA, USDMF | 69 products |
When sending a request, specify which Vinblastine API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Vinblastine API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
